Push to accelerate novel drug reviews promises earlier access to breakthrough therapies for patients long left waiting.

The Chinese firm is aiming to raise US$8 billion in its Hong Kong listing on July 30, making it the city’s biggest share sale in seven years.

Axiom Biosciences founder says Hong Kong investors show greater maturity than Nasdaq in handling biotech companies.

The country’s push to stabilise markets reflects urgency to sustain capital access for tech firms and protect small investors.

Mainland shares are bouncing back from a rout after state investment funds, regulators and companies intervened.

Major financial outlets blast offshore shell structures after case involving the Hong Kong entity of a mainland social media platform.

BYD hits 100,000 EVs in South American country, but calls grow in Europe for higher tariffs on Chinese products to shield local industry.

Heavyweights such as Alibaba gain as analysts bet on business models of locally listed tech companies that differ from US counterparts.

Existing backers Ant Group and Alibaba Group Holding join the equity financing round alongside undisclosed institutional investors.